Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. The award recognizes CEOs who demonstrate exceptional leadership, vision and values in Houston's leading organizations.
The recognition highlights Maetzold's leadership in building Castle Biosciences into a company focused on developing innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma. The company's CFO Frank Stokes praised Maetzold's nearly two-decade tenure for creating a patient-centered culture and driving meaningful progress in personalized disease insights.
Castle Biosciences (Nasdaq: CSTL) ha annunciato che il suo fondatore, presidente e CEO Derek Maetzold è stato nominato CEO più ammirato del 2025 dal Houston Business Journal. Il riconoscimento premia i CEO che dimostrano eccezionali capacità di leadership, visione e valori nelle principali organizzazioni di Houston.
Questo premio mette in evidenza la leadership di Maetzold nel trasformare Castle Biosciences in un'azienda focalizzata sullo sviluppo di test diagnostici innovativi per tumori cutanei, esofago di Barrett e melanoma uveale. Il CFO dell’azienda, Frank Stokes, ha elogiato i quasi vent’anni di Maetzold per aver creato una cultura incentrata sul paziente e per aver guidato progressi significativi nelle diagnosi personalizzate delle malattie.
Castle Biosciences (Nasdaq: CSTL) anunció que su fundador, presidente y CEO Derek Maetzold ha sido nombrado CEO Más Admirado 2025 por el Houston Business Journal. Este premio reconoce a los CEOs que demuestran liderazgo excepcional, visión y valores en las principales organizaciones de Houston.
El reconocimiento destaca el liderazgo de Maetzold en la construcción de Castle Biosciences como una empresa enfocada en desarrollar pruebas diagnósticas innovadoras para cánceres de piel, esófago de Barrett y melanoma uveal. El CFO de la compañía, Frank Stokes, elogió la casi dos décadas de Maetzold por crear una cultura centrada en el paciente y por impulsar avances significativos en el conocimiento personalizado de enfermedades.
Castle Biosciences (나스닥: CSTL)는 창립자이자 사장 겸 CEO인 Derek Maetzold가 휴스턴 비즈니스 저널이 선정한 2025년 가장 존경받는 CEO에 선정되었다고 발표했습니다. 이 상은 휴스턴의 주요 조직에서 탁월한 리더십, 비전 및 가치를 보여준 CEO에게 수여됩니다.
이번 수상은 피부암, Barrett 식도 및 포도막 흑색종 진단을 위한 혁신적인 검사 개발에 집중하는 Castle Biosciences를 구축한 Maetzold의 리더십을 강조합니다. 회사의 CFO인 Frank Stokes는 Maetzold가 거의 20년에 걸쳐 환자 중심 문화를 조성하고 개인 맞춤형 질병 통찰력에서 의미 있는 진전을 이룬 점을 칭찬했습니다.
Castle Biosciences (Nasdaq : CSTL) a annoncé que son fondateur, président et PDG Derek Maetzold a été nommé PDG le plus admiré de 2025 par le Houston Business Journal. Cette distinction récompense les PDG qui font preuve d'un leadership exceptionnel, de vision et de valeurs au sein des principales organisations de Houston.
Cette reconnaissance met en lumière le leadership de Maetzold dans la transformation de Castle Biosciences en une entreprise axée sur le développement de tests diagnostiques innovants pour les cancers de la peau, l'œsophage de Barrett et le mélanome uvéal. Le directeur financier de l'entreprise, Frank Stokes, a salué les près de deux décennies de Maetzold pour avoir instauré une culture centrée sur le patient et avoir fait progresser de manière significative les connaissances personnalisées sur les maladies.
Castle Biosciences (Nasdaq: CSTL) gab bekannt, dass sein Gründer, Präsident und CEO Derek Maetzold vom Houston Business Journal als Most Admired CEO 2025 ausgezeichnet wurde. Die Auszeichnung ehrt CEOs, die außergewöhnliche Führungskompetenz, Vision und Werte in den führenden Organisationen Houstons zeigen.
Die Anerkennung hebt Maetzolds Führung hervor, Castle Biosciences zu einem Unternehmen aufzubauen, das sich auf die Entwicklung innovativer diagnostischer Tests für Hautkrebs, Barrett-Ösophagus und Uvealmelanom konzentriert. Der CFO des Unternehmens, Frank Stokes, lobte Maetzolds fast zwanzigjährige Amtszeit für die Schaffung einer patientenorientierten Unternehmenskultur und den bedeutenden Fortschritt bei personalisierten Krankheitsanalysen.
- None.
- None.
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations
FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated outstanding financial stewardship, fostered inclusive and thriving workplace cultures, and made meaningful contributions to the greater Houston community.
“Derek's visionary leadership and unwavering values have shaped Castle Biosciences into what it is today: a company focused on improving patient outcomes through innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma,” said Frank Stokes, chief financial officer of Castle Biosciences. “Over nearly two decades, his leadership approach has exemplified how great vision and values can drive meaningful progress – building a company culture where patient needs remain at the center of strategic decisions and where personalized disease insights can translate into better care for those who need it most.”
“I am truly honored to receive this recognition from the Houston Business Journal,” said Maetzold. "This award validates our core belief that lasting impact comes from doing right by our team and never losing sight of the patients who depend on our work.”
The award recipients will be honored at a special event held by the Houston Business Journal in August.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ebd01c42-a4d1-47f5-a4e1-5d0f87e16e3a
https://www.globenewswire.com/NewsRoom/AttachmentNg/510a258d-2263-40b2-a51a-947dd2e15f23
FAQ
Who is Derek Maetzold and what award did he receive in 2025?
What diagnostic tests does Castle Biosciences (CSTL) develop?
How long has Derek Maetzold been leading Castle Biosciences (CSTL)?
When will the Houston Business Journal honor the Most Admired CEO award recipients?
